ID   TRIO_HUMAN              Reviewed;        3097 AA.
AC   O75962; D3DTD1; Q13458; Q59EQ7; Q6PJC9; Q6ZN05; Q8IWK8;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-SEP-2009, sequence version 2.
DT   12-OCT-2022, entry version 221.
DE   RecName: Full=Triple functional domain protein;
DE            EC=2.7.11.1;
DE   AltName: Full=PTPRF-interacting protein;
GN   Name=TRIO;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A.,
RA   Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R.,
RA   Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L.,
RA   Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N.,
RA   Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J.,
RA   Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A.,
RA   Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-1686 (ISOFORM 4), AND
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2715-3097 (ISOFORM 1).
RC   TISSUE=Kidney, and Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 38-3097 (ISOFORM 2), FUNCTION, INTERACTION
RP   WITH PTPRF, AND TISSUE SPECIFICITY.
RC   TISSUE=Fibroblast;
RX   PubMed=8643598; DOI=10.1073/pnas.93.11.5466;
RA   Debant A., Serra-Pages C., Seipel K., O'Brien S., Tang M., Park S.-H.,
RA   Streuli M.;
RT   "The multidomain protein Trio binds the LAR transmembrane tyrosine
RT   phosphatase, contains a protein kinase domain, and has separate rac-
RT   specific and rho-specific guanine nucleotide exchange factor domains.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:5466-5471(1996).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 38-3097 (ISOFORM 1).
RA   Streuli M.;
RL   Submitted (SEP-1998) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 362-3097 (ISOFORM 5).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   FUNCTION.
RX   PubMed=10341202; DOI=10.1242/jcs.112.12.1825;
RA   Seipel K., Medley Q.G., Kedersha N.L., Zhang X.A., O'Brien S.P.,
RA   Serra-Pages C., Hemler M.E., Streuli M.;
RT   "Trio amino-terminal guanine nucleotide exchange factor domain expression
RT   promotes actin cytoskeleton reorganization, cell migration and anchorage-
RT   independent cell growth.";
RL   J. Cell Sci. 112:1825-1834(1999).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2282 AND SER-2455, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [12]
RP   INTERACTION WITH CARMIL1.
RX   PubMed=19846667; DOI=10.1091/mbc.e08-10-1071;
RA   Liang Y., Niederstrasser H., Edwards M., Jackson C.E., Cooper J.A.;
RT   "Distinct roles for CARMIL isoforms in cell migration.";
RL   Mol. Biol. Cell 20:5290-5305(2009).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2455 AND SER-2459, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH SORCS2 AND NGFR,
RP   MUTAGENESIS OF LYS-2917, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=22155786; DOI=10.1126/scisignal.2002060;
RA   Deinhardt K., Kim T., Spellman D.S., Mains R.E., Eipper B.A., Neubert T.A.,
RA   Chao M.V., Hempstead B.L.;
RT   "Neuronal growth cone retraction relies on proneurotrophin receptor
RT   signaling through Rac.";
RL   Sci. Signal. 4:RA82-RA82(2011).
RN   [17]
RP   INTERACTION WITH ANKRD26.
RX   PubMed=22666460; DOI=10.1371/journal.pone.0038130;
RA   Liu X.F., Bera T.K., Kahue C., Escobar T., Fei Z., Raciti G.A., Pastan I.;
RT   "ANKRD26 and its interacting partners TRIO, GPS2, HMMR and DIPA regulate
RT   adipogenesis in 3T3-L1 cells.";
RL   PLoS ONE 7:E38130-E38130(2012).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2455; SER-2459 AND SER-2631,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [19]
RP   INVOLVEMENT IN MRD44, AND VARIANTS MRD44 SER-924; HIS-1238; THR-1922;
RP   ASN-1939; VAL-2201; ASP-2247 AND GLN-2707.
RX   PubMed=26721934; DOI=10.1093/hmg/ddv618;
RA   Ba W., Yan Y., Reijnders M.R., Schuurs-Hoeijmakers J.H., Feenstra I.,
RA   Bongers E.M., Bosch D.G., De Leeuw N., Pfundt R., Gilissen C.,
RA   De Vries P.F., Veltman J.A., Hoischen A., Mefford H.C., Eichler E.E.,
RA   Vissers L.E., Nadif Kasri N., De Vries B.B.;
RT   "TRIO loss of function is associated with mild intellectual disability and
RT   affects dendritic branching and synapse function.";
RL   Hum. Mol. Genet. 25:892-902(2016).
RN   [20]
RP   INVOLVEMENT IN MRD44, VARIANTS MRD44 GLN-1428 AND THR-1461, VARIANT MRD63
RP   ILE-1080, CHARACTERIZATION OF VARIANT MRD44 GLN-1428, AND FUNCTION.
RX   PubMed=27418539; DOI=10.1136/jmedgenet-2016-103942;
RA   Pengelly R.J., Greville-Heygate S., Schmidt S., Seaby E.G.,
RA   Jabalameli M.R., Mehta S.G., Parker M.J., Goudie D., Fagotto-Kaufmann C.,
RA   Mercer C., Debant A., Ennis S., Baralle D.;
RT   "Mutations specific to the Rac-GEF domain of TRIO cause intellectual
RT   disability and microcephaly.";
RL   J. Med. Genet. 53:735-742(2016).
RN   [21]
RP   STRUCTURE BY NMR OF 1286-1466, AND MUTAGENESIS.
RX   PubMed=9790533; DOI=10.1016/s0092-8674(00)81757-2;
RA   Liu X., Wang H., Eberstadt M., Schnuchel A., Olejniczak E.T., Meadows R.P.,
RA   Schkeryantz J.M., Janowick D.A., Harlan J.E., Harris E.A.S., Staunton D.E.,
RA   Fesik S.W.;
RT   "NMR structure and mutagenesis of the N-terminal Dbl homology domain of the
RT   nucleotide exchange factor Trio.";
RL   Cell 95:269-277(1998).
RN   [22]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-291; MET-1644; ARG-1690; MET-1978 AND
RP   MET-2242.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [23]
RP   VARIANTS VAL-1368 AND MET-2563.
RX   PubMed=23033978; DOI=10.1056/nejmoa1206524;
RA   de Ligt J., Willemsen M.H., van Bon B.W., Kleefstra T., Yntema H.G.,
RA   Kroes T., Vulto-van Silfhout A.T., Koolen D.A., de Vries P., Gilissen C.,
RA   del Rosario M., Hoischen A., Scheffer H., de Vries B.B., Brunner H.G.,
RA   Veltman J.A., Vissers L.E.;
RT   "Diagnostic exome sequencing in persons with severe intellectual
RT   disability.";
RL   N. Engl. J. Med. 367:1921-1929(2012).
RN   [24]
RP   VARIANTS MRD44 768-GLN--VAL-3097 DEL; LYS-1299; GLN-1428; THR-1461 AND
RP   ARG-1469, VARIANTS MRD63 ILE-1075; GLN-1078; GLY-1078; TRP-1078; ILE-1080
RP   AND LEU-1461, INVOLVEMENT IN MRD63, FUNCTION, CHARACTERIZATION OF VARIANTS
RP   MRD63 ILE-1075; GLN-1078; GLY-1078; TRP-1078; ILE-1080 AND LEU-1461, AND
RP   CHARACTERIZATION OF VARIANTS MRD44 LYS-1299; GLN-1428 AND ARG-1469.
RX   PubMed=32109419; DOI=10.1016/j.ajhg.2020.01.018;
RG   C4RCD Research Group;
RA   Barbosa S., Greville-Heygate S., Bonnet M., Godwin A., Fagotto-Kaufmann C.,
RA   Kajava A.V., Laouteouet D., Mawby R., Wai H.A., Dingemans A.J.M.,
RA   Hehir-Kwa J., Willems M., Capri Y., Mehta S.G., Cox H., Goudie D.,
RA   Vansenne F., Turnpenny P., Vincent M., Cogne B., Lesca G., Hertecant J.,
RA   Rodriguez D., Keren B., Burglen L., Gerard M., Putoux A., Cantagrel V.,
RA   Siquier-Pernet K., Rio M., Banka S., Sarkar A., Steeves M., Parker M.,
RA   Clement E., Moutton S., Tran Mau-Them F., Piton A., de Vries B.B.A.,
RA   Guille M., Debant A., Schmidt S., Baralle D.;
RT   "Opposite modulation of RAC1 by mutations in TRIO is associated with
RT   distinct, domain-specific neurodevelopmental disorders.";
RL   Am. J. Hum. Genet. 106:338-355(2020).
CC   -!- FUNCTION: Guanine nucleotide exchange factor (GEF) for RHOA and RAC1
CC       GTPases (PubMed:8643598, PubMed:22155786, PubMed:27418539). Involved in
CC       coordinating actin remodeling, which is necessary for cell migration
CC       and growth (PubMed:10341202, PubMed:22155786). Plays a key role in the
CC       regulation of neurite outgrowth and lamellipodia formation
CC       (PubMed:32109419). In developing hippocampal neurons, limits dendrite
CC       formation, without affecting the establishment of axon polarity. Once
CC       dendrites are formed, involved in the control of synaptic function by
CC       regulating the endocytosis of AMPA-selective glutamate receptors
CC       (AMPARs) at CA1 excitatory synapses (By similarity). May act as a
CC       regulator of adipogenesis (By similarity).
CC       {ECO:0000250|UniProtKB:F1M0Z1, ECO:0000269|PubMed:10341202,
CC       ECO:0000269|PubMed:22155786, ECO:0000269|PubMed:27418539,
CC       ECO:0000269|PubMed:32109419, ECO:0000269|PubMed:8643598}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- SUBUNIT: Interacts with CARMIL1 (PubMed:19846667). Interacts with
CC       PTPRF/LAR (PubMed:8643598). Interacts with ANKRD26 (PubMed:22666460).
CC       Interacts with Bassoon/BSN and Piccolo/PCLO (By similarity). Interacts
CC       with the cytoplasmic region of the heterodimer formed by NGFR and
CC       SORCS2. ProNGF binding mediates dissociation of TRIO from the receptor
CC       complex (PubMed:22155786). {ECO:0000250|UniProtKB:F1M0Z1,
CC       ECO:0000269|PubMed:19846667, ECO:0000269|PubMed:22155786,
CC       ECO:0000269|PubMed:22666460, ECO:0000269|PubMed:8643598}.
CC   -!- INTERACTION:
CC       O75962; Q9NRI5: DISC1; NbExp=3; IntAct=EBI-718519, EBI-529989;
CC       O75962-4; P63000-1: RAC1; NbExp=2; IntAct=EBI-15915736, EBI-7212896;
CC       O75962-4; Q811T9-1: Disc1; Xeno; NbExp=2; IntAct=EBI-15915736, EBI-15881527;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000305|PubMed:22155786}. Cell
CC       projection {ECO:0000250|UniProtKB:Q0KL02}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=O75962-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O75962-2; Sequence=VSP_004467, VSP_004468;
CC       Name=3;
CC         IsoId=O75962-3; Sequence=VSP_023306, VSP_023307;
CC       Name=4;
CC         IsoId=O75962-4; Sequence=VSP_037860;
CC       Name=5;
CC         IsoId=O75962-5; Sequence=VSP_037861, VSP_037862;
CC   -!- TISSUE SPECIFICITY: Widely expressed, with highest levels in heart,
CC       skeletal muscle, and brain. {ECO:0000269|PubMed:8643598}.
CC   -!- DOMAIN: The N-terminal DBL/GEF domain specifically catalyzes nucleotide
CC       exchange for RAC1, leading to the activation of Jun kinase and the
CC       production of membrane ruffles. The second DBL/GEF domain is an
CC       exchange factor for rhoa and induces the formation of stress fibers.
CC   -!- PTM: Phosphorylated on serine residue(s).
CC   -!- DISEASE: Intellectual developmental disorder, autosomal dominant 44,
CC       with microcephaly (MRD44) [MIM:617061]: A disorder characterized by
CC       developmental delay, variable intellectual disability, distinctive
CC       facial features, and abnormalities of the fingers. Most patients also
CC       have microcephaly. {ECO:0000269|PubMed:26721934,
CC       ECO:0000269|PubMed:27418539, ECO:0000269|PubMed:32109419}. Note=The
CC       disease may be caused by variants affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Intellectual developmental disorder, autosomal dominant 63,
CC       with macrocephaly (MRD63) [MIM:618825]: An autosomal dominant form of
CC       intellectual disability, a disorder characterized by significantly
CC       below average general intellectual functioning associated with
CC       impairments in adaptive behavior and manifested during the
CC       developmental period. MRD63 is characterized by moderate to severe
CC       impaired intellectual development with poor or absent speech, global
CC       developmental delay, and variable behavioral abnormalities. Variable
CC       dysmorphic features are preset in half of the patients.
CC       {ECO:0000269|PubMed:27418539, ECO:0000269|PubMed:32109419}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr
CC       protein kinase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC34245.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAC34245.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=AAC43042.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAC34245.1; Type=Frameshift; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/TRIOID43542ch5p15.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK131423; BAD18570.1; -; mRNA.
DR   EMBL; AC010419; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC016549; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC016654; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC016656; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC026456; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471102; EAX08047.1; -; Genomic_DNA.
DR   EMBL; CH471102; EAX08048.1; -; Genomic_DNA.
DR   EMBL; BC035585; AAH35585.1; -; mRNA.
DR   EMBL; BC017268; AAH17268.1; -; mRNA.
DR   EMBL; U42390; AAC34245.1; ALT_SEQ; mRNA.
DR   EMBL; AF091395; AAC43042.1; ALT_INIT; mRNA.
DR   EMBL; AB209754; BAD92991.1; -; mRNA.
DR   CCDS; CCDS3883.1; -. [O75962-1]
DR   RefSeq; NP_009049.2; NM_007118.3. [O75962-1]
DR   RefSeq; XP_011512412.1; XM_011514110.2. [O75962-4]
DR   PDB; 1NTY; X-ray; 1.70 A; A=1284-1594.
DR   PDB; 2NZ8; X-ray; 2.00 A; B=1285-1594.
DR   PDB; 6D8Z; X-ray; 2.65 A; A/B/C=1960-2275.
DR   PDBsum; 1NTY; -.
DR   PDBsum; 2NZ8; -.
DR   PDBsum; 6D8Z; -.
DR   SMR; O75962; -.
DR   BioGRID; 113055; 78.
DR   DIP; DIP-37578N; -.
DR   IntAct; O75962; 38.
DR   MINT; O75962; -.
DR   STRING; 9606.ENSP00000339299; -.
DR   ChEMBL; CHEMBL4523153; -.
DR   iPTMnet; O75962; -.
DR   PhosphoSitePlus; O75962; -.
DR   BioMuta; TRIO; -.
DR   EPD; O75962; -.
DR   jPOST; O75962; -.
DR   MassIVE; O75962; -.
DR   MaxQB; O75962; -.
DR   PaxDb; O75962; -.
DR   PeptideAtlas; O75962; -.
DR   PRIDE; O75962; -.
DR   ProteomicsDB; 50323; -. [O75962-1]
DR   ProteomicsDB; 50324; -. [O75962-2]
DR   ProteomicsDB; 50325; -. [O75962-3]
DR   ProteomicsDB; 50326; -. [O75962-4]
DR   ProteomicsDB; 50327; -. [O75962-5]
DR   ABCD; O75962; 4 sequenced antibodies.
DR   Antibodypedia; 2116; 82 antibodies from 19 providers.
DR   DNASU; 7204; -.
DR   Ensembl; ENST00000344135.5; ENSP00000339291.5; ENSG00000038382.21. [O75962-3]
DR   Ensembl; ENST00000344204.9; ENSP00000339299.4; ENSG00000038382.21. [O75962-1]
DR   GeneID; 7204; -.
DR   KEGG; hsa:7204; -.
DR   MANE-Select; ENST00000344204.9; ENSP00000339299.4; NM_007118.4; NP_009049.2.
DR   UCSC; uc003jff.4; human. [O75962-1]
DR   CTD; 7204; -.
DR   DisGeNET; 7204; -.
DR   GeneCards; TRIO; -.
DR   GeneReviews; TRIO; -.
DR   HGNC; HGNC:12303; TRIO.
DR   HPA; ENSG00000038382; Low tissue specificity.
DR   MalaCards; TRIO; -.
DR   MIM; 601893; gene.
DR   MIM; 617061; phenotype.
DR   MIM; 618825; phenotype.
DR   neXtProt; NX_O75962; -.
DR   OpenTargets; ENSG00000038382; -.
DR   Orphanet; 476126; Micrognathia-recurrent infections-behavioral abnormalities-mild intellectual disability syndrome.
DR   PharmGKB; PA36982; -.
DR   VEuPathDB; HostDB:ENSG00000038382; -.
DR   eggNOG; KOG0032; Eukaryota.
DR   eggNOG; KOG4240; Eukaryota.
DR   GeneTree; ENSGT00940000154766; -.
DR   HOGENOM; CLU_000288_76_3_1; -.
DR   InParanoid; O75962; -.
DR   OMA; HTHVKEX; -.
DR   OrthoDB; 5761at2759; -.
DR   PhylomeDB; O75962; -.
DR   TreeFam; TF318080; -.
DR   PathwayCommons; O75962; -.
DR   Reactome; R-HSA-193648; NRAGE signals death through JNK.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   Reactome; R-HSA-416482; G alpha (12/13) signalling events.
DR   Reactome; R-HSA-418885; DCC mediated attractive signaling.
DR   Reactome; R-HSA-8980692; RHOA GTPase cycle.
DR   Reactome; R-HSA-9013148; CDC42 GTPase cycle.
DR   Reactome; R-HSA-9013149; RAC1 GTPase cycle.
DR   Reactome; R-HSA-9013404; RAC2 GTPase cycle.
DR   Reactome; R-HSA-9013408; RHOG GTPase cycle.
DR   Reactome; R-HSA-9013409; RHOJ GTPase cycle.
DR   Reactome; R-HSA-9013423; RAC3 GTPase cycle.
DR   SignaLink; O75962; -.
DR   SIGNOR; O75962; -.
DR   BioGRID-ORCS; 7204; 25 hits in 1105 CRISPR screens.
DR   ChiTaRS; TRIO; human.
DR   EvolutionaryTrace; O75962; -.
DR   GeneWiki; TRIO_(gene); -.
DR   GenomeRNAi; 7204; -.
DR   Pharos; O75962; Tbio.
DR   PRO; PR:O75962; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; O75962; protein.
DR   Bgee; ENSG00000038382; Expressed in sural nerve and 195 other tissues.
DR   ExpressionAtlas; O75962; baseline and differential.
DR   Genevisible; O75962; HS.
DR   GO; GO:0042995; C:cell projection; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0019898; C:extrinsic component of membrane; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005085; F:guanyl-nucleotide exchange factor activity; IBA:GO_Central.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:ProtInc.
DR   GO; GO:0007411; P:axon guidance; IBA:GO_Central.
DR   GO; GO:0007417; P:central nervous system development; IEA:InterPro.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; ISS:UniProtKB.
DR   GO; GO:0048812; P:neuron projection morphogenesis; IMP:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IEA:InterPro.
DR   GO; GO:0051056; P:regulation of small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0007185; P:transmembrane receptor protein tyrosine phosphatase signaling pathway; TAS:ProtInc.
DR   CDD; cd00160; RhoGEF; 2.
DR   CDD; cd00170; SEC14; 1.
DR   CDD; cd00176; SPEC; 6.
DR   Gene3D; 1.20.900.10; -; 2.
DR   Gene3D; 2.30.29.30; -; 2.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 3.40.525.10; -; 1.
DR   InterPro; IPR001251; CRAL-TRIO_dom.
DR   InterPro; IPR036865; CRAL-TRIO_dom_sf.
DR   InterPro; IPR035899; DBL_dom_sf.
DR   InterPro; IPR000219; DH-domain.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR028570; Kalirin/TRIO.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR036028; SH3-like_dom_sf.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR018159; Spectrin/alpha-actinin.
DR   InterPro; IPR002017; Spectrin_repeat.
DR   PANTHER; PTHR22826:SF104; PTHR22826:SF104; 1.
DR   Pfam; PF00650; CRAL_TRIO; 1.
DR   Pfam; PF07679; I-set; 1.
DR   Pfam; PF00169; PH; 2.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00621; RhoGEF; 2.
DR   Pfam; PF00018; SH3_1; 1.
DR   Pfam; PF00435; Spectrin; 4.
DR   SMART; SM00409; IG; 1.
DR   SMART; SM00408; IGc2; 1.
DR   SMART; SM00233; PH; 2.
DR   SMART; SM00325; RhoGEF; 2.
DR   SMART; SM00220; S_TKc; 1.
DR   SMART; SM00516; SEC14; 1.
DR   SMART; SM00326; SH3; 2.
DR   SMART; SM00150; SPEC; 6.
DR   SUPFAM; SSF48065; SSF48065; 2.
DR   SUPFAM; SSF48726; SSF48726; 1.
DR   SUPFAM; SSF50044; SSF50044; 2.
DR   SUPFAM; SSF52087; SSF52087; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50191; CRAL_TRIO; 1.
DR   PROSITE; PS50010; DH_2; 2.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 2.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS50002; SH3; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell projection;
KW   Cytoplasm; Disease variant; Disulfide bond;
KW   Guanine-nucleotide releasing factor; Immunoglobulin domain;
KW   Intellectual disability; Kinase; Nucleotide-binding; Phosphoprotein;
KW   Reference proteome; Repeat; Serine/threonine-protein kinase; SH3 domain;
KW   Transferase.
FT   CHAIN           1..3097
FT                   /note="Triple functional domain protein"
FT                   /id="PRO_0000080978"
FT   DOMAIN          65..210
FT                   /note="CRAL-TRIO"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00056"
FT   REPEAT          311..418
FT                   /note="Spectrin 1"
FT   REPEAT          538..644
FT                   /note="Spectrin 2"
FT   REPEAT          878..984
FT                   /note="Spectrin 3"
FT   REPEAT          1109..1216
FT                   /note="Spectrin 4"
FT   DOMAIN          1292..1467
FT                   /note="DH 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00062"
FT   DOMAIN          1480..1591
FT                   /note="PH 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   DOMAIN          1656..1721
FT                   /note="SH3 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   DOMAIN          1969..2145
FT                   /note="DH 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00062"
FT   DOMAIN          2157..2271
FT                   /note="PH 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   DOMAIN          2551..2616
FT                   /note="SH3 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   DOMAIN          2685..2775
FT                   /note="Ig-like C2-type"
FT   DOMAIN          2796..3052
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1601..1650
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1779..1906
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1927..1965
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2287..2552
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2639..2660
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1628..1650
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1806..1835
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1836..1855
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1878..1906
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1931..1955
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2319..2340
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2353..2371
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2372..2390
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2397..2414
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2480..2513
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2524..2552
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        2915
FT                   /evidence="ECO:0000250"
FT   BINDING         2802..2810
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         2825
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         1627
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q0KL02"
FT   MOD_RES         1632
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:F1M0Z1"
FT   MOD_RES         1633
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:F1M0Z1"
FT   MOD_RES         1824
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:F1M0Z1"
FT   MOD_RES         2282
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         2455
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         2459
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         2631
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   DISULFID        2696..2759
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   VAR_SEQ         1..2501
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_023306"
FT   VAR_SEQ         1..59
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_037860"
FT   VAR_SEQ         2368
FT                   /note="G -> E (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:8643598"
FT                   /id="VSP_004467"
FT   VAR_SEQ         2369..2544
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:8643598"
FT                   /id="VSP_004468"
FT   VAR_SEQ         2502..2544
FT                   /note="FPGDSDSLQRQTPRHAAPGKDTDRMSTCSSASEQSVQSTQSNG -> MLPSQ
FT                   AQGLLWWVFPLFPASSLSYPPVSYRADGLARNTFLKAC (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_023307"
FT   VAR_SEQ         2545..2563
FT                   /note="SESSSSSNISTMLVTHDYT -> VSASGGPRPPAPLPLSRQL (in
FT                   isoform 5)"
FT                   /evidence="ECO:0000303|Ref.7"
FT                   /id="VSP_037861"
FT   VAR_SEQ         2564..3097
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|Ref.7"
FT                   /id="VSP_037862"
FT   VARIANT         291
FT                   /note="S -> T (in dbSNP:rs55772118)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041899"
FT   VARIANT         348
FT                   /note="D -> E (in dbSNP:rs16903367)"
FT                   /id="VAR_059802"
FT   VARIANT         768..3097
FT                   /note="Missing (in MRD44)"
FT                   /evidence="ECO:0000269|PubMed:32109419"
FT                   /id="VAR_083915"
FT   VARIANT         924
FT                   /note="R -> S (in MRD44; unknown pathological significance;
FT                   dbSNP:rs772072746)"
FT                   /evidence="ECO:0000269|PubMed:26721934"
FT                   /id="VAR_077093"
FT   VARIANT         1075
FT                   /note="T -> I (in MRD63; slightly increased occipitofrontal
FT                   circumference; increased activation of RAC1-mediated
FT                   signaling; increased lamellipodia formation)"
FT                   /evidence="ECO:0000269|PubMed:32109419"
FT                   /id="VAR_083916"
FT   VARIANT         1078
FT                   /note="R -> G (in MRD63; increased activation of
FT                   RAC1-mediated signaling; increased neurite outgrowth)"
FT                   /evidence="ECO:0000269|PubMed:32109419"
FT                   /id="VAR_083917"
FT   VARIANT         1078
FT                   /note="R -> Q (in MRD63; increased activation of
FT                   RAC1-mediated signaling; increased neurite outgrowth)"
FT                   /evidence="ECO:0000269|PubMed:32109419"
FT                   /id="VAR_083918"
FT   VARIANT         1078
FT                   /note="R -> W (in MRD63; increased activation of
FT                   RAC1-mediated signaling; increased neurite outgrowth;
FT                   dbSNP:rs1554065887)"
FT                   /evidence="ECO:0000269|PubMed:32109419"
FT                   /id="VAR_083919"
FT   VARIANT         1080
FT                   /note="N -> I (in MRD63; slightly increased occipitofrontal
FT                   circumference; increased activation of RAC1-mediated
FT                   signaling; increased neurite outgrowth; dbSNP:rs879255628)"
FT                   /evidence="ECO:0000269|PubMed:27418539,
FT                   ECO:0000269|PubMed:32109419"
FT                   /id="VAR_077094"
FT   VARIANT         1238
FT                   /note="Y -> H (in MRD44; unknown pathological significance;
FT                   dbSNP:rs756004023)"
FT                   /evidence="ECO:0000269|PubMed:26721934"
FT                   /id="VAR_077095"
FT   VARIANT         1299
FT                   /note="E -> K (in MRD44; severely decreased activation of
FT                   RAC1-mediated signaling; severely decreased neurite
FT                   outgrowth)"
FT                   /evidence="ECO:0000269|PubMed:32109419"
FT                   /id="VAR_083920"
FT   VARIANT         1368
FT                   /note="D -> V (found in patient with severe intellectual
FT                   disability; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:23033978"
FT                   /id="VAR_069371"
FT   VARIANT         1428
FT                   /note="R -> Q (in MRD44; severely decreased activation of
FT                   RAC1-mediated signaling; severely decreased neurite
FT                   outgrowth; dbSNP:rs879255626)"
FT                   /evidence="ECO:0000269|PubMed:27418539,
FT                   ECO:0000269|PubMed:32109419"
FT                   /id="VAR_077096"
FT   VARIANT         1461
FT                   /note="P -> L (in MRD63; slightly increased occipitofrontal
FT                   circumference; slightly increased RAC1-mediated signaling;
FT                   slightly increased neurite outgrowth)"
FT                   /evidence="ECO:0000269|PubMed:32109419"
FT                   /id="VAR_083921"
FT   VARIANT         1461
FT                   /note="P -> T (in MRD44; no effect on RAC1-mediated
FT                   signaling; no effect on neurite outgrowth;
FT                   dbSNP:rs879255627)"
FT                   /evidence="ECO:0000269|PubMed:27418539,
FT                   ECO:0000269|PubMed:32109419"
FT                   /id="VAR_077097"
FT   VARIANT         1469
FT                   /note="H -> R (in MRD44; decreased activation of
FT                   RAC1-mediated signaling; severely decreased neurite
FT                   outgrowth; dbSNP:rs1554070777)"
FT                   /evidence="ECO:0000269|PubMed:32109419"
FT                   /id="VAR_083922"
FT   VARIANT         1613
FT                   /note="A -> T (in dbSNP:rs16903474)"
FT                   /id="VAR_059803"
FT   VARIANT         1644
FT                   /note="T -> M (in dbSNP:rs55687522)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041900"
FT   VARIANT         1690
FT                   /note="H -> R (in dbSNP:rs56292586)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041901"
FT   VARIANT         1922
FT                   /note="A -> T (in MRD44; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:26721934"
FT                   /id="VAR_077098"
FT   VARIANT         1939
FT                   /note="S -> N (in MRD44; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:26721934"
FT                   /id="VAR_077099"
FT   VARIANT         1978
FT                   /note="V -> M (in a metastatic melanoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041902"
FT   VARIANT         2201
FT                   /note="L -> V (in MRD44; unknown pathological significance;
FT                   dbSNP:rs771342869)"
FT                   /evidence="ECO:0000269|PubMed:26721934"
FT                   /id="VAR_077100"
FT   VARIANT         2242
FT                   /note="T -> M (in dbSNP:rs55916212)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041903"
FT   VARIANT         2247
FT                   /note="E -> D (in MRD44; unknown pathological significance;
FT                   dbSNP:rs1258664728)"
FT                   /evidence="ECO:0000269|PubMed:26721934"
FT                   /id="VAR_077101"
FT   VARIANT         2563
FT                   /note="T -> M (found in patient with severe intellectual
FT                   disability; unknown pathological significance;
FT                   dbSNP:rs751663099)"
FT                   /evidence="ECO:0000269|PubMed:23033978"
FT                   /id="VAR_069372"
FT   VARIANT         2707
FT                   /note="R -> Q (in MRD44; unknown pathological significance;
FT                   dbSNP:rs768858988)"
FT                   /evidence="ECO:0000269|PubMed:26721934"
FT                   /id="VAR_077102"
FT   MUTAGEN         1299
FT                   /note="E->A: 50% decrease in nucleotide exchange activity."
FT                   /evidence="ECO:0000269|PubMed:9790533"
FT   MUTAGEN         1303
FT                   /note="T->A: 40% decrease in nucleotide exchange activity."
FT                   /evidence="ECO:0000269|PubMed:9790533"
FT   MUTAGEN         1389
FT                   /note="N->A: No change in nucleotide exchange activity."
FT                   /evidence="ECO:0000269|PubMed:9790533"
FT   MUTAGEN         1426
FT                   /note="V->A: 90% decrease in nucleotide exchange activity."
FT                   /evidence="ECO:0000269|PubMed:9790533"
FT   MUTAGEN         1427
FT                   /note="Q->A: 80% decrease in nucleotide exchange activity."
FT                   /evidence="ECO:0000269|PubMed:9790533"
FT   MUTAGEN         1428
FT                   /note="R->A: 80% decrease in nucleotide exchange activity."
FT                   /evidence="ECO:0000269|PubMed:9790533"
FT   MUTAGEN         1430
FT                   /note="T->A: 80% decrease in nucleotide exchange activity."
FT                   /evidence="ECO:0000269|PubMed:9790533"
FT   MUTAGEN         1431
FT                   /note="K->A: Loss of nucleotide exchange activity."
FT                   /evidence="ECO:0000269|PubMed:9790533"
FT   MUTAGEN         1434
FT                   /note="L->A: 40% decrease in nucleotide exchange activity."
FT                   /evidence="ECO:0000269|PubMed:9790533"
FT   MUTAGEN         1437
FT                   /note="K->A: No change in nucleotide exchange activity."
FT                   /evidence="ECO:0000269|PubMed:9790533"
FT   MUTAGEN         1438
FT                   /note="E->A: 30% decrease in nucleotide exchange activity."
FT                   /evidence="ECO:0000269|PubMed:9790533"
FT   MUTAGEN         2917
FT                   /note="K->A: Expected to disrupt kinase activity. Causes
FT                   reorganization of the actin cytoskeleton in the absence of
FT                   NGF."
FT                   /evidence="ECO:0000269|PubMed:22155786"
FT   CONFLICT        550..553
FT                   /note="QLEN -> HVRT (in Ref. 5; AAC34245 and 6; AAC43042)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        574
FT                   /note="D -> E (in Ref. 5; AAC34245 and 6; AAC43042)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        787..788
FT                   /note="QL -> HV (in Ref. 5; AAC34245 and 6; AAC43042)"
FT                   /evidence="ECO:0000305"
FT   HELIX           1291..1316
FT                   /evidence="ECO:0007829|PDB:1NTY"
FT   HELIX           1318..1324
FT                   /evidence="ECO:0007829|PDB:1NTY"
FT   TURN            1331..1335
FT                   /evidence="ECO:0007829|PDB:1NTY"
FT   HELIX           1337..1341
FT                   /evidence="ECO:0007829|PDB:1NTY"
FT   HELIX           1344..1353
FT                   /evidence="ECO:0007829|PDB:1NTY"
FT   HELIX           1355..1361
FT                   /evidence="ECO:0007829|PDB:1NTY"
FT   TURN            1362..1364
FT                   /evidence="ECO:0007829|PDB:1NTY"
FT   HELIX           1366..1369
FT                   /evidence="ECO:0007829|PDB:1NTY"
FT   HELIX           1370..1375
FT                   /evidence="ECO:0007829|PDB:1NTY"
FT   TURN            1376..1380
FT                   /evidence="ECO:0007829|PDB:1NTY"
FT   HELIX           1381..1400
FT                   /evidence="ECO:0007829|PDB:1NTY"
FT   TURN            1401..1403
FT                   /evidence="ECO:0007829|PDB:1NTY"
FT   HELIX           1404..1412
FT                   /evidence="ECO:0007829|PDB:1NTY"
FT   HELIX           1418..1422
FT                   /evidence="ECO:0007829|PDB:1NTY"
FT   HELIX           1424..1441
FT                   /evidence="ECO:0007829|PDB:1NTY"
FT   HELIX           1450..1470
FT                   /evidence="ECO:0007829|PDB:1NTY"
FT   STRAND          1473..1475
FT                   /evidence="ECO:0007829|PDB:1NTY"
FT   HELIX           1481..1483
FT                   /evidence="ECO:0007829|PDB:1NTY"
FT   STRAND          1486..1495
FT                   /evidence="ECO:0007829|PDB:1NTY"
FT   STRAND          1497..1501
FT                   /evidence="ECO:0007829|PDB:1NTY"
FT   STRAND          1504..1523
FT                   /evidence="ECO:0007829|PDB:1NTY"
FT   STRAND          1529..1538
FT                   /evidence="ECO:0007829|PDB:1NTY"
FT   HELIX           1539..1541
FT                   /evidence="ECO:0007829|PDB:1NTY"
FT   STRAND          1542..1545
FT                   /evidence="ECO:0007829|PDB:1NTY"
FT   STRAND          1549..1552
FT                   /evidence="ECO:0007829|PDB:2NZ8"
FT   STRAND          1554..1562
FT                   /evidence="ECO:0007829|PDB:1NTY"
FT   TURN            1565..1567
FT                   /evidence="ECO:0007829|PDB:1NTY"
FT   STRAND          1569..1572
FT                   /evidence="ECO:0007829|PDB:1NTY"
FT   HELIX           1576..1592
FT                   /evidence="ECO:0007829|PDB:1NTY"
FT   HELIX           1968..1992
FT                   /evidence="ECO:0007829|PDB:6D8Z"
FT   HELIX           1995..2002
FT                   /evidence="ECO:0007829|PDB:6D8Z"
FT   HELIX           2006..2008
FT                   /evidence="ECO:0007829|PDB:6D8Z"
FT   TURN            2009..2011
FT                   /evidence="ECO:0007829|PDB:6D8Z"
FT   HELIX           2012..2016
FT                   /evidence="ECO:0007829|PDB:6D8Z"
FT   HELIX           2019..2028
FT                   /evidence="ECO:0007829|PDB:6D8Z"
FT   HELIX           2030..2035
FT                   /evidence="ECO:0007829|PDB:6D8Z"
FT   HELIX           2036..2038
FT                   /evidence="ECO:0007829|PDB:6D8Z"
FT   HELIX           2043..2050
FT                   /evidence="ECO:0007829|PDB:6D8Z"
FT   TURN            2051..2053
FT                   /evidence="ECO:0007829|PDB:6D8Z"
FT   HELIX           2054..2056
FT                   /evidence="ECO:0007829|PDB:6D8Z"
FT   HELIX           2057..2075
FT                   /evidence="ECO:0007829|PDB:6D8Z"
FT   TURN            2076..2078
FT                   /evidence="ECO:0007829|PDB:6D8Z"
FT   HELIX           2079..2087
FT                   /evidence="ECO:0007829|PDB:6D8Z"
FT   HELIX           2093..2120
FT                   /evidence="ECO:0007829|PDB:6D8Z"
FT   HELIX           2126..2148
FT                   /evidence="ECO:0007829|PDB:6D8Z"
FT   STRAND          2151..2153
FT                   /evidence="ECO:0007829|PDB:6D8Z"
FT   HELIX           2159..2161
FT                   /evidence="ECO:0007829|PDB:6D8Z"
FT   STRAND          2164..2173
FT                   /evidence="ECO:0007829|PDB:6D8Z"
FT   STRAND          2184..2200
FT                   /evidence="ECO:0007829|PDB:6D8Z"
FT   STRAND          2212..2219
FT                   /evidence="ECO:0007829|PDB:6D8Z"
FT   HELIX           2220..2222
FT                   /evidence="ECO:0007829|PDB:6D8Z"
FT   STRAND          2223..2226
FT                   /evidence="ECO:0007829|PDB:6D8Z"
FT   STRAND          2235..2242
FT                   /evidence="ECO:0007829|PDB:6D8Z"
FT   STRAND          2245..2252
FT                   /evidence="ECO:0007829|PDB:6D8Z"
FT   HELIX           2256..2270
FT                   /evidence="ECO:0007829|PDB:6D8Z"
SQ   SEQUENCE   3097 AA;  346900 MW;  EA9236DF88B0EA24 CRC64;
     MSGSSGGAAA PAASSGPAAA ASAAGSGCGG GAGEGAEEAA KDLADIAAFF RSGFRKNDEM
     KAMDVLPILK EKVAYLSGGR DKRGGPILTF PARSNHDRIR QEDLRRLISY LACIPSEEVC
     KRGFTVIVDM RGSKWDSIKP LLKILQESFP CCIHVALIIK PDNFWQKQRT NFGSSKFEFE
     TNMVSLEGLT KVVDPSQLTP EFDGCLEYNH EEWIEIRVAF EDYISNATHM LSRLEELQDI
     LAKKELPQDL EGARNMIEEH SQLKKKVIKA PIEDLDLEGQ KLLQRIQSSE SFPKKNSGSG
     NADLQNLLPK VSTMLDRLHS TRQHLHQMWH VRKLKLDQCF QLRLFEQDAE KMFDWITHNK
     GLFLNSYTEI GTSHPHAMEL QTQHNHFAMN CMNVYVNINR IMSVANRLVE SGHYASQQIR
     QIASQLEQEW KAFAAALDER STLLDMSSIF HQKAEKYMSN VDSWCKACGE VDLPSELQDL
     EDAIHHHQGI YEHITLAYSE VSQDGKSLLD KLQRPLTPGS SDSLTASANY SKAVHHVLDV
     IHEVLHHQRQ LENIWQHRKV RLHQRLQLCV FQQDVQQVLD WIENHGEAFL SKHTGVGKSL
     HRARALQKRH EDFEEVAQNT YTNADKLLEA AEQLAQTGEC DPEEIYQAAH QLEDRIQDFV
     RRVEQRKILL DMSVSFHTHV KELWTWLEEL QKELLDDVYA ESVEAVQDLI KRFGQQQQTT
     LQVTVNVIKE GEDLIQQLRD SAISSNKTPH NSSINHIETV LQQLDEAQSQ MEELFQERKI
     KLELFLQLRI FERDAIDIIS DLESWNDELS QQMNDFDTED LTIAEQRLQH HADKALTMNN
     LTFDVIHQGQ DLLQYVNEVQ ASGVELLCDR DVDMATRVQD LLEFLHEKQQ ELDLAAEQHR
     KHLEQCVQLR HLQAEVKQVL GWIRNGESML NAGLITASSL QEAEQLQREH EQFQHAIEKT
     HQSALQVQQK AEAMLQANHY DMDMIRDCAE KVASHWQQLM LKMEDRLKLV NASVAFYKTS
     EQVCSVLESL EQEYKREEDW CGGADKLGPN SETDHVTPMI SKHLEQKEAF LKACTLARRN
     ADVFLKYLHR NSVNMPGMVT HIKAPEQQVK NILNELFQRE NRVLHYWTMR KRRLDQCQQY
     VVFERSAKQA LEWIHDNGEF YLSTHTSTGS SIQHTQELLK EHEEFQITAK QTKERVKLLI
     QLADGFCEKG HAHAAEIKKC VTAVDKRYRD FSLRMEKYRT SLEKALGISS DSNKSSKSLQ
     LDIIPASIPG SEVKLRDAAH ELNEEKRKSA RRKEFIMAEL IQTEKAYVRD LRECMDTYLW
     EMTSGVEEIP PGIVNKELII FGNMQEIYEF HNNIFLKELE KYEQLPEDVG HCFVTWADKF
     QMYVTYCKNK PDSTQLILEH AGSYFDEIQQ RHGLANSISS YLIKPVQRIT KYQLLLKELL
     TCCEEGKGEI KDGLEVMLSV PKRANDAMHL SMLEGFDENI ESQGELILQE SFQVWDPKTL
     IRKGRERHLF LFEMSLVFSK EVKDSSGRSK YLYKSKLFTS ELGVTEHVEG DPCKFALWVG
     RTPTSDNKIV LKASSIENKQ DWIKHIREVI QERTIHLKGA LKEPIHIPKT APATRQKGRR
     DGEDLDSQGD GSSQPDTISI ASRTSQNTLD SDKLSGGCEL TVVIHDFTAC NSNELTIRRG
     QTVEVLERPH DKPDWCLVRT TDRSPAAEGL VPCGSLCIAH SRSSMEMEGI FNHKDSLSVS
     SNDASPPASV ASLQPHMIGA QSSPGPKRPG NTLRKWLTSP VRRLSSGKAD GHVKKLAHKH
     KKSREVRKSA DAGSQKDSDD SAATPQDETV EERGRNEGLS SGTLSKSSSS GMQSCGEEEG
     EEGADAVPLP PPMAIQQHSL LQPDSQDDKA SSRLLVRPTS SETPSAAELV SAIEELVKSK
     MALEDRPSSL LVDQGDSSSP SFNPSDNSLL SSSSPIDEME ERKSSSLKRR HYVLQELVET
     ERDYVRDLGY VVEGYMALMK EDGVPDDMKG KDKIVFGNIH QIYDWHRDFF LGELEKCLED
     PEKLGSLFVK HERRLHMYIA YCQNKPKSEH IVSEYIDTFF EDLKQRLGHR LQLTDLLIKP
     VQRIMKYQLL LKDFLKYSKK ASLDTSELER AVEVMCIVPR RCNDMMNVGR LQGFDGKIVA
     QGKLLLQDTF LVTDQDAGLL PRCRERRIFL FEQIVIFSEP LDKKKGFSMP GFLFKNSIKV
     SCLCLEENVE NDPCKFALTS RTGDVVETFI LHSSSPSVRQ TWIHEINQIL ENQRNFLNAL
     TSPIEYQRNH SGGGGGGGSG GSGGGGGSGG GGAPSGGSGH SGGPSSCGGA PSTSRSRPSR
     IPQPVRHHPP VLVSSAASSQ AEADKMSGTS TPGPSLPPPG AAPEAGPSAP SRRPPGADAE
     GSEREAEPIP KMKVLESPRK GAANASGSSP DAPAKDARAS LGTLPLGKPR AGAASPLNSP
     LSSAVPSLGK EPFPPSSPLQ KGGSFWSSIP ASPASRPGSF TFPGDSDSLQ RQTPRHAAPG
     KDTDRMSTCS SASEQSVQST QSNGSESSSS SNISTMLVTH DYTAVKEDEI NVYQGEVVQI
     LASNQQNMFL VFRAATDQCP AAEGWIPGFV LGHTSAVIVE NPDGTLKKST SWHTALRLRK
     KSEKKDKDGK REGKLENGYR KSREGLSNKV SVKLLNPNYI YDVPPEFVIP LSEVTCETGE
     TVVLRCRVCG RPKASITWKG PEHNTLNNDG HYSISYSDLG EATLKIVGVT TEDDGIYTCI
     AVNDMGSASS SASLRVLGPG MDGIMVTWKD NFDSFYSEVA ELGRGRFSVV KKCDQKGTKR
     AVATKFVNKK LMKRDQVTHE LGILQSLQHP LLVGLLDTFE TPTSYILVLE MADQGRLLDC
     VVRWGSLTEG KIRAHLGEVL EAVRYLHNCR IAHLDLKPEN ILVDESLAKP TIKLADFGDA
     VQLNTTYYIH QLLGNPEFAA PEIILGNPVS LTSDTWSVGV LTYVLLSGVS PFLDDSVEET
     CLNICRLDFS FPDDYFKGVS QKAKEFVCFL LQEDPAKRPS AALALQEQWL QAGNGRSTGV
     LDTSRLTSFI ERRKHQNDVR PIRSIKNFLQ SRLLPRV
//
